Stock Events

Stock Events

Immunovia AB 

SEK0.3100
7
+SEK0.00+0.32% Monday 13:18

Statistics

Day High
0.319
Day Low
0.305
52W High
0.33
52W Low
0.2685
Volume
2,773,752
Avg. Volume
6,512,773
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

26NovExpected
Q2 2025
Q3 2025
-0.11
-0.09
-0.07
-0.05
Expected EPS
-0.047135221975823996
Actual EPS
N/A

Financials

-8,221.37%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
931,000Revenue
-76.54MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Guardant Health
GH
Mkt Cap21.67B
Guardant Health provides liquid biopsy tests for cancer diagnostics, overlapping with Immunovia's focus on early cancer detection using blood-based biomarkers.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG develops diagnostic tools and technologies for detecting various diseases including cancer, similar to Immunovia's diagnostic solutions.
Illumina
ILMN
Mkt Cap32.55B
Illumina, Inc. offers genomic sequencing solutions used in cancer and other health diagnostics, competing in the broader market of molecular diagnostics.
Qiagen NV
QGEN
Mkt Cap8.9B
Qiagen N.V. provides sample and assay technologies for molecular diagnostics, competing with Immunovia in the field of precision medicine and diagnostics.
Quest Diagnostics
DGX
Mkt Cap26.79B
Quest Diagnostics incorporates advanced diagnostics for conditions including cancer, directly competing with Immunovia's diagnostic tests.
Bio-Rad Laboratories
BIO
Mkt Cap10.37B
Bio-Rad Laboratories, Inc. specializes in clinical diagnostics and life science research, offering products that compete in the diagnostics market.
Fulgent Genetics
FLGT
Mkt Cap539.57M
Fulgent Genetics, Inc. focuses on genetic testing to detect cancer and other diseases, competing with Immunovia's genomic and proteomic testing approaches.
Myriad Genetics
MYGN
Mkt Cap302.25M
Myriad Genetics, Inc. provides molecular diagnostic tests that assess the risk of developing cancer, competing with Immunovia's focus on early detection and risk assessment.

About

Immunovia AB engages in the development of methods for diagnosing complex forms of cancer and autoimmune diseases. Its technology platform, IMMray, focuses on the early diagnosis of cancer, predicts disease progression, and monitors therapeutic responsiveness of cancers. The company was founded by Karl Arne Krister Borrebaeck on May 24, 2007 and is headquartered in Lund, Sweden.
Show more...
CEO
Jeff Borcherding
Employees
13
Country
Sweden
ISIN
SE0026578346

Listings

MU
DE
1YR.MU
LSE
GB
0G8X.LSE
ST
SE
IMMNOV.ST
F
DE
1YR.F

0 Comments

Share your thoughts

FAQ

What is Immunovia AB stock price today?▼
The current price of IMMNOV-BTA.ST is SEK0.31 SEK — it has increased by +0.32% in the past 24 hours. Watch Immunovia AB stock price performance more closely on the chart.
What is Immunovia AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Stockholm Exchange exchange Immunovia AB stocks are traded under the ticker IMMNOV-BTA.ST.
What is Immunovia AB revenue for the last year?▼
Immunovia AB revenue for the last year amounts to 931,000 SEK.
What is Immunovia AB net income for the last year?▼
IMMNOV-BTA.ST net income for the last year is -76.54M SEK.
How many employees does Immunovia AB have?▼
As of September 06, 2026, the company has 13 employees.
In which sector is Immunovia AB located?▼
Immunovia AB operates in the Health & Wellness sector.
When did Immunovia AB complete a stock split?▼
Immunovia AB has not had any recent stock splits.
Where is Immunovia AB headquartered?▼
Immunovia AB is headquartered in Lund, Sweden.